Effect of different location of atrial lead position on nearfield and farfield electrograms in dual chamber pacemaker-defibrillators.

The normal functioning of dual chamber pacemaker-cardioverter defibrillator (AV pacer/ICD) may be affected by oversensing of the farfield R wave (FFRW) by the atrial channel. This study aimed to investigate whether placement of the AV pacer/ICD's atrial lead at a lateral (LAT) wall location compared to a medial (MED) location i.e. the appendage of the right atrium, would reduce the amplitude of FFRWs but not the nearfield atrial electrograms (AEGMs) during sinus rhythm (SR) and ventricular fibrillation (VF). In 17 patients, real time electrograms were recorded during SR and induced VF through the atrial lead initially at the MED and subsequently at the LAT location. In 10 patients the electrograms in SR were also recorded on a computerized data acquisition and recording system at different band-pass filter settings. Although FFRWs were recorded both at MED and LAT locations, they were much smaller, 3.5+/-4.1mm during SR and 1.7+/-2.2mm during VF at the LAT location. At 30-500Hz band-pass filter, lower amplitudes of FFRWs 0.14+/-0.09 mV were recorded at the LAT location. The V/A ratios of the amplitudes of FFRWs and AEGMs were smaller at the LAT location during SR and VF. The nearfield AEGMs were of similar amplitudes at the MED and LAT locations. These data indicate that lower amplitudes of FFRWs are recorded by placement of the atrial lead at the lateral wall of the right atrium. Oversensing of FFRWs may be prevented to improve functioning of the AV pacer-ICD.

Efficacy and safety of catheter ablation in octogenarians.

OBJECTIVES: To determine whether catheter ablation is safe and effective in patients over the age of 80. BACKGROUND: There is a tendency to withhold invasive therapy in the elderly until it has been proven safe and effective. METHODS: Over a two-year period from February 1, 1996 to February 1, 1998, 695 consecutive patients underwent 744 catheter ablation procedures of supraventricular and ventricular arrhythmias. These patients were divided into three groups based on age: > or =80 years, 60 to 79 years and <60 years. Acute ablation success, using standard criteria and complication rates for these three groups were determined. RESULTS: There were 37 patients > or =80 years, 275 patients 60 to 79 years and 383 patients <60 years old. The overall acute ablation success rate for the entire group was 95% with no difference in rates among the three groups (97%, > or =80 years; 94%, 60-79 years; 95%, <60 years). The percentage of patients undergoing His bundle ablation was greatest in the > or =80-year-old group (43% vs. 19% vs. 2%, p < 0.01), and the percentage of patients undergoing accessory pathway ablation was greatest in the <60-year-old patients (0% vs. 4% vs. 25%, p < 0.01). The overall complication rate for the entire group was 2.6%, and there was only one major/life-threatening complication. There was no difference in complication rates among the groups (0%, > or =80 years; 2.2%, 60 to 79 years; 3.1%, <60 years). Based on the sample size, the 95% confidence interval is 0% to 7.8% for an adverse event in the octogenarian. CONCLUSIONS: Catheter ablative therapy for the arrhythmias attempted in the very elderly appears to be effective with low risk. Ablation results appear to be comparable with those noted in younger patients.

Learning retention in patients receiving midazolam during permanent pacemaker implantation.

This pilot study (N = 20) tested the effects of intravenous midazolam administration on learning retention after pacemaker implantation. Patients were randomized to receive teaching at 1 or 3 hours after the last dose of midazolam. Using a standardized teaching format, one of two study nurses performed the teaching that included incision care, activity restrictions, environmental factors potentially affecting pacemaker function, and follow-up requirements. Learning was evaluated by one of the investigators blinded to teaching time. Subjects in the 1-hour group retained significantly less information than those taught at 3 hours after drug administration. Patients taught later answered similar numbers of questions correctly, whereas there was much more variability in correct responses for the group taught earlier. This article reviews the effects of midazolam on memory and learning as well as provides suggestions for alterations in patient education protocols for patients receiving midazolam for pacemaker implantation. The effect of shortened length of stay on care practices is also discussed.

Extraction and replacement of permanent pacemaker leads through occluded vessels: use of extraction sheaths as conduits--balloon venoplasty as an adjunct.

Patients (pts) may present for lead extraction with symptomatic or asymptomatic subclavian vein or superior vena cava thrombosis. Replacement of permanent pacemaker leads (PPLs) in these pts may be difficult and may require accessing a new site. We examined the utility of replacing PPLs through completely occluded vessels using extraction sheaths as conduits through the total occlusion. Over six years, a total of 210 atrial and/or ventricular PPLs were extracted from 137 pts. Two pts presented with angiographically documented thrombotic occlusion of the subclavian vein. One additional pt. who had presented with a superior vena cava (SVC) syndrome, had a totally occluded innominate vein and SVC occlusion. Balloon venoplasty was used as an adjunct to dilate the SVC. In all pts, after PPLs were removed via a subclavian extraction sheath through the occluded vessel, the retained sheath was used to place a guide wire, then a peel away dilating sheath, to insert new PPLs, in each case on the side of total venous occlusion. Seven PPLs and two lead fragments were extracted, and five new PPLs replaced, ipsilateral to the venous occlusion. These data show that extraction of PPLs through thrombosed veins may be performed successfully and may not require replacing the leads through a new site. This technique spares the pt the need to access the opposite subclavian vein, and it avoids an excessive number of PPLs in the subclavian vein and SVC. The procedure illustrates an efficient means to reintroduce new PPLs with the potential to reduce associated morbidity, since repeat puncture of the subclavian vein is not required. Safety of the procedure as a whole must be considered with regard to the known risks of lead extraction, some complications of which may be substantial using current techniques.

Upper rate lockout: an unexpected feature of rate adaptive atrioventricular delay.

We present a case in which use of rate adaptive AV delay resulted in unexpected pacemaker 2:1 AV block when the patient's atrial rate exceeded the pacemaker maximum tracking rate but was below the predicted multiblock rate. "Lockout" of normal upper rate behavior was accompanied with the requirement of a slower atrial rate for reassociation than loss of atrial tracking, a form of upper rate hysteresis. The mechanism of upper rate lockout is discussed, along with potential ways to avoid the problem. The use of software based pacemakers with an extended range of programmable options allows the most flexibility in optimizing pacemaker performance in an individual patient.

Comparison of epicardial and endocardial programmed stimulation in patients at risk for ventricular arrhythmias after cardiac surgery.

Programmed ventricular stimulation was performed on 36 patients after recent cardiac surgery using implanted right ventricular epicardial temporary wires and with catheters positioned percutaneously at two right ventricular endocardial sites. Patients were followed for a mean of 18.5 months (range 3 to 36 months). Epicardial wires were nonfunctional in 10 patients (28%) due to excessively high pacing thresholds. Overall, 22 patients (61%) had inducible sustained ventricular tachycardia; epicardial wires were functional in 15 (68%) of these patients. Six patients without inducible ventricular tachycardia with epicardial stimulation were inducible using endocardial stimulation. Of the 24 patients in whom epicardial and endocardial ventricular stimulation could be performed, concordant results were obtained in only 17 (71%), despite similar epicardial and endocardial ventricular effective and functional refractory periods. A total of 14 arrhythmic events occurred during the follow-up period. Of the 22 patients with an inducible sustained ventricular tachycardia, 12 (64%) had subsequent arrhythmic events. Only 2 of the 14 noninducible patients had follow-up arrhythmic events, one of which was caused by medication proarrhythmia. Endocardial ventricular stimulation had a superior sensitivity (83% versus 30%, P < 0.0001) and an improved negative predictive value (86% versus 61%, P < 0.05) compared with epicardial ventricular stimulation. These results indicate that noninducibility using epicardial programmed ventricular stimulation does not reliably portend a low risk for recurrent ventricular tachyarrhythmias. Epicardial programmed stimulation, used alone, may be inadequate for postoperative electrophysiological evaluation of patients at risk for ventricular arrhythmias.

Clinical experience with a new multiprogrammable dual chamber pacemaker.

We evaluated the clinical performance of a new dual chamber pacemaker, ELA Chorus, in 35 patients. This device incorporates linear rate adaptive AV delay (AVDR), rate smoothing, fallback, impedance telemetry, pacemaker mediated tachycardia (PMT) recognition and reprogramming software, intracardiac electrogram displays, autothreshold testing, diagnostic data, battery depletion curves, and laptop computer programming. Mean patient age was 68 years; 18 patients had AV block, six had sinus node dysfunction (one with AV block), nine had carotid sinus hypersensitivity (three with AV block), and two had vagally mediated syncope. At hospital discharge, programming was DDD with a mean low rate of 60 (50-70) beats/min, mean high rate of 126 (120-154) beats/min; AVDR was ON in 21 patients, rate smoothing ON in six patients, fallback ON in six patients, and PMT reprogramming algorithm ON in 27 patients. Pacemaker follow-up involved 500 clinic visits over 14.3 months (1-36). Three patients developed atrial fibrillation, reprogrammed to DDI mode (two patients) or fallback (one patient). Fallback was used 617 times. PMT occurred 427 times in six patients; the PMT algorithm reprogrammed AV delay and postventricular atrial refractory period (PVARP) automatically, a function unique to the Chorus. Intracardiac electrograms and autothreshold testing improved follow-up efficiency. This new dual chamber pacemaker enhances programming flexibility and improves diagnostic accuracy at follow-up.

Clinical evaluation of the patient with ventricular arrhythmia.

Evaluation of patients with ventricular arrhythmia (VA) is a frequently encountered problem in clinical practice. Determining which patients require treatment and which are at risk for sudden cardiac death remains challenging, however. Classification of VAs as significant, prognostically important, having unknown importance, or insignificant will help determine whether treatment is warranted and beneficial. Tests for evaluating suspected VA, including ambulatory electrocardiographic monitoring, exercise testing, and electrophysiologic studies, are used to determine the presence or frequency of an arrhythmia, correlate the arrhythmia with symptoms, determine a prognosis, or evaluate the efficacy of drug therapy.

Programmable external automatic antitachycardia pacing as a bridge to definitive therapy in patients with recurrent sustained ventricular tachycardia.

The efficacy and safety of external programmable automatic antitachycardia pacemakers (ATPs) used in the critical care setting for recurrent sustained monomorphic ventricular tachycardia (VT) was evaluated. Ten patients who had failed a mean of 4.0 +/- 1.4 antiarrhythmic medications (range 2-7) and who had previously required electrical cardioversion for VT were enrolled. Prior to ATP use, successful overdrive pacing termination of VT was demonstrated in all patients. Intertach (Intermedics, Inc.; n = 9) and Orthocor II (Cordis, Inc.; n = 1) ATPs were attached to temporary bipolar transvenous or epicardial pacing leads. Mean patient age was 66.4 +/- 11.5 years, and mean left ventricular ejection fraction was 22 +/- 7.5%. At the time of initial ATP use, mean VT cycle length was 347 +/- 88 msec (range 280-550 msec). A burst scanning antitachycardia pacing algorithm was used in each patient; one patient was also treated with a fixed rate burst adapted to VT cycle length. The duration of ATP use ranged from 2-25 days (median 5), successfully terminating greater than 3,369 VT episodes (median 3, range 0 to greater than 3,103 episodes per-patient). Two episodes of ATP induced rate acceleration occurred, each successfully terminated by the ATP. Only two patients required external cardioversion during ATP use, one for primary ventricular fibrillation and one for rapid polymorphic VT associated with antiarrhythmic drug withdrawal. ATPs also provided antibradycardia pacing and allowed for serial programmed ventricular stimulation. No complications were associated with transvenous catheter or ATP use.(ABSTRACT TRUNCATED AT 250 WORDS)

Encainide dosing in patients with severe renal dysfunction: report of a case and literature review.

Dosage of encainide for patients with lethal ventricular arrhythmias is based on pharmacodynamic effects and efficacy of arrhythmia suppression, coupled with metabolizer phenotype and extent of renal and hepatic dysfunction. Decreased clearance in patients with renal dysfunction necessitates a reduction in dosage to avoid toxic and dose-related proarrhythmic effects. This case represents a patient with severe renal dysfunction and sustained ventricular tachycardia who achieved electrophysiologically guided suppression of induced ventricular tachycardia at a steady-state encainide dose of only 25 mg daily, significantly lower than package insert or compendial recommendations for initial dosage in patients with renal insufficiency. Documented "therapeutic" metabolite concentrations correlated to electrophysiologic response. Literature review illustrates the complexity of encainide dosage in such individuals and underscores the need for therapeutic drug monitoring to individualize dosage.

Use of programmed stimulation in identifying patients at high risk for sudden cardiac death.

Sudden cardiac death accounts for 60% of the total cardiovascular mortality in the United States. Individuals after myocardial infarction or with chronic left ventricular dysfunction are known to be at increased risk. Noninvasive studies have been applied to these populations, but the predictive accuracy of these tests is low. Investigators have used programmed stimulation attempting to identify patients at increased risk and guide their treatment. The prognostic utility of programmed ventricular stimulation for prediction of sudden cardiac death in these populations is reviewed.

Supraventricular tachycardia: diagnosis and treatment.

Specific mechanisms of supraventricular tachycardia include sinoatrial, intra-atrial, atrioventricular (AV) nodal as well as concealed and manifest bypass tract reentry. In dual pathway reentry, at least one of the pathways involves the AV node, usually the slow pathway and the other pathway, perinodal fibers within the atria. Localization of the perinodal fibers is critical for ablative procedures to eliminate AV nodal tachycardias. Other mechanisms of supraventricular tachycardia include chaotic atrial tachycardia and automatic atrial tachycardia with and without AV block. However, drug therapy includes intravenous adenosine 6 mg, as well as the older standbys of digoxin, calcium and beta-blocking agents, and type 1a and 1c antiarrhythmias. In resistance cases, amiodarone is usually effective. However, for incessant supraventricular mechanisms, catheter or surgical ablative techniques are recommended to eliminate long-term drug administration.

Hereditary long QT syndrome associated with cardiac conduction system disease.

This report describes the cardiac conduction abnormalities, detected by invasive electrophysiological study, in two identical siblings with symptomatic congenital long QT syndrome. Both patients had evidence of intra-Hisian conduction delay in response to programmed atrial stimulation and pacing induced infranodal block was seen in one of the two patients. The response of the observed conduction delay to autonomic interventions is described. The observed electrophysiologic abnormalities are consistent with previously reported pathological findings and document the association of functional conduction system disease with congenital QT prolongation.

Risk profiling the patient after acute myocardial infarction.

Patients surviving acute myocardial infarction form a large, heterogeneous group at risk for few or many varied complications with widely varied prognoses. By examining fundamental aspects of cardiac function such as left ventricular function, electrical instability, and residual ischemia as well as comorbid factors such as diabetes, a patient's risk for subsequent morbidity and mortality may be predicted. It is hoped that by identifying patients at increased risk, one may be able to alter the natural history of their disease.